Product Description
BET inhibitor INCB057643 binds to the acetylated lysine recognition motifs found in the BRD of BET proteins, thereby preventing the interaction between the BET proteins and acetylated lysines on histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes, such as c-Myc-dependent target genes, may lead to an inhibition of tumor cell growth. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bet-inhibitor-incb057643)
Mechanisms of Action: BET Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Incyte
Company Location: WILMINGTON DE 19803
Company CEO: Hervé Hoppenot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Finland, Italy, Japan, Netherlands, Spain, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Myelodysplastic Syndrome|Myelodysplastic-Myeloproliferative Diseases|Myelofibrosis|Myeloproliferative Disorders|Polycythemia Vera|Preleukemia|Thrombocythemia, Essential|Thrombocytosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LIMBER | P1 |
Recruiting |
Myeloproliferative Disorders|Thrombocytosis|Preleukemia|Thrombocythemia, Essential|Myelodysplastic-Myeloproliferative Diseases|Polycythemia Vera|Myelofibrosis|Myelodysplastic Syndrome |
2025-12-30 |
|
| jRCT2041220002 | P1 |
Recruiting |
Myelofibrosis|Myelodysplastic Syndrome |
2024-11-11 |